For research use only. Not for therapeutic Use.
Iptacopan (Cat No.:I019006) is a targeted therapeutic agent that acts as a selective inhibitor of complement factor B, a key component of the alternative pathway of the complement system. By inhibiting factor B, Iptacopan helps to modulate the immune response, reducing excessive complement activation that contributes to various autoimmune and inflammatory conditions. It has been investigated for its potential in treating diseases such as paroxysmal nocturnal hemoglobinuria (PNH), C3 glomerulopathy, and other complement-mediated disorders. Clinical trials have shown promising results in improving disease outcomes with fewer side effects compared to traditional complement inhibitors.
| Catalog Number | I019006 |
| CAS Number | 1644670-37-0 |
| Molecular Formula | C₂₅H₃₀N₂O₄ |
| Purity | ≥95% |
| Target | Complement System |
| IUPAC Name | 4-[(2S,4S)-4-ethoxy-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]piperidin-2-yl]benzoic acid |
| InChI | InChI=1S/C25H30N2O4/c1-4-31-19-10-12-27(22(14-19)17-5-7-18(8-6-17)25(28)29)15-21-20-9-11-26-24(20)16(2)13-23(21)30-3/h5-9,11,13,19,22,26H,4,10,12,14-15H2,1-3H3,(H,28,29)/t19-,22-/m0/s1 |
| InChIKey | RENRQMCACQEWFC-UGKGYDQZSA-N |
| SMILES | CCO[C@H]1CCN([C@@H](C1)C2=CC=C(C=C2)C(=O)O)CC3=C(C=C(C4=C3C=CN4)C)OC |
| Reference | [1]. Dimitrios C Mastellos, et al. Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria. Semin Hematol. 2018 Jul;55(3):167-175.<br>[2]. Anna Schubart, et al. Small-molecule Factor B Inhibitor for the Treatment of Complement-Mediated Diseases. Proc Natl Acad Sci U S A. 2019 Apr 16;116(16):7926-7931.<br>[3]. Nello Mainolfi, et al. Discovery of 4-((2 S,4 S)-4-Ethoxy-1-((5-methoxy-7-methyl-1 H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases. J Med Chem. 2020 Jun 11;63(11):5697-5722. |
